Vertex Reports Third-Quarter Revenue of $3.44 Billion, EPS of $2.56
Revenue rose 11.8% year over year to $3.44 billion, while net income fell 39.6% to $653.6 million and diluted EPS declined 39% to $2.56. Cystic fibrosis therapies and newer products supported revenue growth.
Vertex Pharmaceuticals reported third-quarter 2026 revenue of $3.44 billion, up 11.8% from the prior-year quarter, while net income fell 39.6% to $653.6 million and diluted EPS declined 39% to $2.56. Growth in cystic fibrosis therapies and newer products supported revenue gains.Financial Highlights…